Tuesday 13 October 2026 Export OSCR’s income statement to Excel — free account

Oscar Health, Inc.

Oscar Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.7 billion, up 27.5% from fiscal 2024. In the quarter to June 2026, revenue grew 70.4%, EPS grew 234.8%, free cash flow grew 316.3% and total debt rose 43.9%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

33.79 0.22 −0.65%

Follow OSCR

Alert me

Market cap: $10.5B
P/E: 19.8×
Fwd P/E: 29.7×
Dividend yield: —
F-score: 3/9
Altman Z: 1.07
Beneish M: −2.18
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 11.92

Total sells 150.02

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	1	—	—	—	—	—	—
Sell	1	6	3	—	5	—	2	8	1	2	6	—

Insider Ownership 16.39%

Capital & Financial Ratios $m

Market Cap 10,500.00

Revenue 15,318.63

Net Income 550.93

Free Cash Flow 4,379.95

Net Debt (3,643.98)

Current Ratio 0.57

Debt/Equity 0.21

P/E ratio 19.76

Fwd P/E 29.70

P/S ratio 0.67

P/B ratio 4.97

Past 5Y EPS Growth —

This Y EPS Growth 214.41%

Next Y EPS Growth 23.44%

Next Y revenue growth 60.08%

Next 5Y EPS Growth 114.55%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 77.39%

10-year low 10-year high

P/B against its own 10 years 97.63%

10-year low 10-year high

EV/Sales against its own 10 years 82.03%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1,870	1,527	2,774	4,076
Receivables	253	381	499	757
Inventory	—	—	—	—
Other	—	—	—	—
	2,124	1,908	3,273	4,833

	2023	2024	2025	Q'26
Payables	2,363	3,389	4,696	8,522
ST’ Debt	—	—	—	—
Other	—	—	—	—
	2,363	3,389	4,696	8,522

Compound Annual Growth %

	10y	5y	3y
Sales	—	90.80%	43.45%
Cash Flow	—	37.50%	42.25%
Earnings	—	0.00%	0.00%
Book Value	—	16.91%	3.20%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	4,647	4,880	—	—	—
’25	3,046	2,864	2,986	2,805	11,701
’24	2,142	2,219	2,423	2,392	9,178
’23	1,470	1,522	1,440	1,432	5,863
’22	973	1,017	978	995	3,964
’21	369	529	444	496	1,839
’20	88	115	102	158	463

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	2,619	2,092	—	—	—
’25	879	509	(965)	672	1,095
’24	634	497	(500)	347	978
’23	415	166	(1,149)	297	(272)
’22	563	214	(548)	151	380
’21	318	55	(589)	34	(182)
’20	106	246	(219)	89	223

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	2,610	2,081	—	—	—
’25	870	500	(974)	663	1,058
’24	628	490	(508)	340	950
’23	407	160	(1,156)	291	(298)
’22	557	208	(558)	144	351
’21	311	49	(595)	27	(208)
’20	102	242	(222)	86	209

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	2.07	1.10	—	—	—
’25	0.92	(0.89)	(0.53)	(1.24)	(1.69)
’24	0.62	0.20	(0.22)	(0.62)	0.10
’23	(0.18)	(0.07)	(0.29)	(0.66)	(1.22)
’22	(0.36)	(0.53)	(0.91)	(1.05)	(2.85)
’21	(0.98)	(0.35)	(1.02)	(0.95)	(3.20)
’20	(3.36)	(1.42)	(2.72)	(6.41)	(13.90)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	7.51	2.05	2.39	8.44	11.20	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	37.00	10.53	9.89	23.79	23.80
People
People	Employees	—	—	—	—	1,839	2,621	2,714	2,400	2,400	2,305
	Revenue/emp, $m	—	—	—	0.00	0.25	0.70	1.46	2.44	3.82	5.08
Income, $m
Income, $m	Revenue	—	—	—	488	463	1,839	3,964	5,863	9,178	11,701
	Gross margin, %	—	—	—	16.37	33.16	11.68	17.23	20.82	20.10	14.38
	EBT	—	—	—	(259)	(406)	(571)	(610)	(267)	33	(437)
	EBT margin, %	—	—	—	(53.13)	(87.68)	(31.03)	(15.39)	(4.56)	0.36	(3.74)
	Net income	—	—	—	(261)	(407)	(571)	(610)	(271)	26	(443)
	Depreciation	—	—	—	0	14	23	18	2	6	1
Per share, $
Per share, $	Revenue	—	—	—	16.94	15.82	10.27	18.65	26.45	38.18	44.60
	Earnings	—	—	—	(9.06)	(13.90)	(3.20)	(2.85)	(1.22)	0.11	(1.69)
	Cash flow	—	—	—	(5.74)	7.61	(1.02)	1.79	(1.23)	4.07	4.17
	Capex	—	—	—	(0.90)	(0.48)	(0.14)	(0.14)	(0.12)	(0.12)	(0.14)
	Free cash flow	—	—	—	(6.64)	7.13	(1.16)	1.65	(1.34)	3.95	4.03
	Book value	—	—	—	12.17	15.34	7.78	4.20	3.64	4.23	3.74
	Shares, m	—	—	—	29	29	179	212	222	240	262
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	79.06	0.00
	P/S	—	—	—	2.20	2.20	0.76	0.13	0.34	0.35	0.32
	P/B	—	—	—	0.00	0.00	1.01	0.59	2.50	3.18	3.84
	EV/Sales	—	—	—	0.72	0.72	0.24	(0.19)	0.08	0.22	0.12
	EV/FCF	—	—	—	1.60	1.60	(2.14)	(2.10)	(1.50)	2.11	1.35
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(165)	223	(182)	380	(272)	978	1,095
	Capex	—	—	—	(26)	(14)	(26)	(29)	(26)	(28)	(36)
	Free cash flow	—	—	—	(191)	209	(208)	351	(298)	950	1,058
Balance, $m
Balance, $m	Working capital	—	—	—	(570)	(671)	(494)	(1,360)	(240)	(1,481)	(1,424)
	Total debt	—	—	—	—	142	—	298	299	300	430
	Net debt	—	—	—	(337)	(684)	(1,104)	(1,261)	(1,572)	(1,228)	(2,344)
	Shareholders’ equity	—	—	—	351	449	1,393	892	806	1,016	981
Returns, %
Returns, %	ROA	—	—	—	(20.62)	(22.89)	(20.47)	(15.45)	(6.66)	0.60	(7.94)
	ROIC	—	—	—	(1,161.14)	0.00	(117.94)	0.00	0.00	0.00	0.00
	ROE	—	—	—	23.31	36.97	(1,185.16)	(53.07)	(31.88)	2.79	(44.38)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ELV Elevance Health, Inc.	$91.5B	18.8×	20.3×	+1.40% (above 0%: growing)	−13.08% (below 0%: shrinking)	−9.01% (below 0%: shrinking)	15.77%	4.56%	Compare
CI Cigna Group	$74.9B	11.7×	11.4×	+6.68% (above 0%: growing)	+10.16% (above 0%: growing)	+66.93% (above 0%: growing)	88.24%	3.73%	Compare
HUM Humana Inc.	$52.1B	39.5×	42.9×	+26.18% (above 0%: growing)	+27.88% (above 0%: growing)	+58.51% (above 0%: growing)	13.45%	3.33%	Compare
CNC Centene Corporation	$33.1B	— (loss-making)	24.8×	+9.92% (above 0%: growing)	n/m	+116.61% (above 0%: growing)	8.59%	2.24%	Compare
MOH Molina Healthcare, Inc	$10.7B	— (loss-making)	55.0×	−4.84% (below 0%: shrinking)	−74.95% (below 0%: shrinking)	+5.81% (above 0%: growing)	13.19%	1.33%	Compare
OSCR Oscar Health, Inc.	$10.5B	19.8×	29.7×	+70.40% (above 0%: growing)	n/m	+316.29% (above 0%: growing)	22.25%	7.96%
CLOV Clover Health Investments, Corp.	$2.5B	— (loss-making)	292×	+55.60% (above 0%: growing)	n/m	+406.43% (above 0%: growing)	20.59%	3.77%	Compare
PGNY Progyny, Inc.	$2.2B	28.2×	19.9×	+5.30% (above 0%: growing)	+80.00% (above 0%: growing)	−12.01% (below 0%: shrinking)	25.48%	11.41%	Compare
ALHC Alignment Healthcare, Inc.	$1.7B	39.5×	80.3×	+31.55% (above 0%: growing)	+125.00% (above 0%: growing)	−229.51% (below 0%: shrinking)	13.55%	3.15%	Compare
Median of peers	$21.9B	28.2×	33.9×	+8.30%	+19.02%	+32.16%	14.66%	3.53%

All 12 Healthcare Plans stocks →

Oscar Health, Inc. (OSCR) key facts

Strength: Oscar Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.7 billion, up 27.5% from fiscal 2024.
Oscar Health, Inc. (OSCR) is a Healthcare Plans company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 13, 2026, OSCR traded at $33.79, a market capitalization of $10.5 billion.
Return on equity was −44.4% and debt-to-equity 0.21.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 1.07 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.